ArticleFrontiers in oncology2026
Metaplastic breast carcinoma with osteosarcomatous differentiation: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metaplastic breast carcinoma (MBC) is a rare and aggressive malignancy accounting for less than 0.2-1% of all breast cancers. MBC with osteosarcomatous differentiation is extremely rare (0.003%-0.12%) and presents significant diagnostic and therapeutic challenges. Case presentation: We report a case of a 65-year-old female with history of breast-conserving surgery for left breast invasive carcinoma in 2021, who presented with a recurrent left breast mass in December 2025. After adjuvant therapy including ACT chemotherapy, radiotherapy and capecitabine, imaging revealed a 4.47 x 3.4 x 2.8 cm irregular mass with calcifications. Core needle biopsy suggested metaplastic carcinoma. After 4 cycles of TP plus immunotherapy showing stable disease, modified radical mastectomy was performed. Final pathology confirmed MBC with osteosarcomatous differentiation (4.5 x 3 x 3 cm), triple-negative with SATB2 positivity and Ki-67 70%. Postoperative BRCA1/2 testing was negative, and adjuvant AC chemotherapy combined with immunotherapy was administered. Conclusion: This case highlights the diagnostic challenges and treatment considerations for MBC with osteosarcomatous differentiation. Multimodality treatment including surgery, anthracycline-based chemotherapy, immunotherapy, and radiotherapy may provide optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.